PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION

Lobbying client · Virginia · filed 2025 to 2026

Labor-Management Cooperation Organization in the Pharmaceutical Industry

$1,252,000 Reported spend

36 Filings counted

6 Outside firms hired

12 Bills named

Spend is reported income plus in-house expenses across 36 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 6 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION.

Who filed for this client 6

E3 STRATEGIC CONSULTING GROUP $380,000 Outside firm · 7 filings
TIBER CREEK GROUP $350,000 Outside firm · 7 filings
DAVE KOLBE CONSULTING $210,000 Outside firm · 7 filings
MR. CHRISTOPHER HEINZ $210,000 Outside firm · 7 filings
FLYNN & ASSOCIATES, INC. $60,000 Outside firm · 1 filing
MCCARTER & ENGLISH, LLP $42,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 12

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…

8 filings
S. 1040
Drug Competition Enhancement Act

7 filings
H.R. 4317
PBM Reform Act of 2025

6 filings
H.R. 5256 (119th Congress)
340B ACCESS Act

5 filings
S. 2658
Medication Affordability and Patent Integrity Act

5 filings
S. 3345
PBM Price Transparency and Accountability Act

5 filings
H.R. 2880
Protecting Patients Against PBM Abuses Act

1 filing
H.R. 5256 (118th Congress)
Medicare Access to Rural Anesthesiology Act of 2023

1 filing
S. 2305
Biosimilar Red Tape Elimination Act

1 filing
H.R. 9393
Lower Costs, More Transparency Act of 2026

1 filing
S. 1414
Expedited Access to Biosimilars Act

1 filing
S. 3014
Ensuring Timely Access to Generics Act of 2025

1 filing

Reported by year 2 years

2026 $528,000 15 filings
2025 $724,000 21 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 35
SENATE 22

Recent filings 37 total

Q3 report

MR. CHRISTOPHER HEINZ

3rd Quarter 2026 (July 1 - Sep 30) · House · $30,000 income · posted Oct 22, 2026

View → Q3 report

MCCARTER & ENGLISH, LLP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $6,000 income · posted Oct 20, 2026

View → Q3 report

TIBER CREEK GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 18, 2026

View → Q3 report

DAVE KOLBE CONSULTING

3rd Quarter 2026 (July 1 - Sep 30) · House · $30,000 income · posted Oct 9, 2026

View → Q3 report

E3 STRATEGIC CONSULTING GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 5, 2026

View → Q2 report

MCCARTER & ENGLISH, LLP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $6,000 income · posted Aug 4, 2026

View → Q2 report

MR. CHRISTOPHER HEINZ

2nd Quarter 2026 (Apr 1 - June 30) · House · $30,000 income · posted Aug 3, 2026

View → Q2 report

TIBER CREEK GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 18, 2026

View → Q2 report

E3 STRATEGIC CONSULTING GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 9, 2026

View → Q2 report

DAVE KOLBE CONSULTING

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $30,000 income · posted Jul 6, 2026

View → Q1 report

MR. CHRISTOPHER HEINZ

1st Quarter 2026 (Jan 1 - Mar 31) · House · $30,000 income · posted May 4, 2026

View → Q1 report

TIBER CREEK GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026

View → Q1 report

MCCARTER & ENGLISH, LLP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $6,000 income · posted Apr 20, 2026

View → Q1 report

E3 STRATEGIC CONSULTING GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · $60,000 income · posted Apr 6, 2026

View → Q1 report

DAVE KOLBE CONSULTING

1st Quarter 2026 (Jan 1 - Mar 31) · House · $30,000 income · posted Apr 5, 2026

View → Q4 report

MR. CHRISTOPHER HEINZ

4th Quarter 2025 (Oct 1 - Dec 31) · House · $30,000 income · posted Jan 27, 2026

View → Q4 report

MCCARTER & ENGLISH, LLP

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $6,000 income · posted Jan 26, 2026

View → Q4 report

TIBER CREEK GROUP

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 17, 2026

View → Q4 report

E3 STRATEGIC CONSULTING GROUP

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 16, 2026

View → Q4 amendmentNo activity

DAVE KOLBE CONSULTING

4th Quarter 2025 (Oct 1 - Dec 31) · $30,000 income · posted Jan 14, 2026

View →

Showing the 20 most recent of 37 filings. Search the explorer for "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION".

Keep going

Filings through October 22, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.